Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats.

ABSTRACT: Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need for systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, which integrates direct vascularization for facile mass transfer and localized immunosuppressant delivery for islet rejection prophylaxis. Here, we investigated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent, male rat model. We demonstrated that allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and functional, reverting diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppressio

SUBMITTER: Paez-Mayorga J 

PROVIDER: S-EPMC9792517 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature